Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ALK
REST API REST API
Homo sapiens
ALK is differentially expressed in 184 experiments: 125 organism parts: lung, prostate, ... (123 more);, 143 disease states: normal, acute promyelocytic leukemia, ... (141 more);, 54 cell types 127 cell lines 18 compound treatments and 64 other conditions.
Synonyms CD246
Orthologs F1MUQ3_BOVIN (Bos taurus)   Alk (Rattus norvegicus)   F1NHS4_CHICK (Gallus gallus)   Alk (Mus musculus)   Alk (Drosophila melanogaster)   alk (Danio rerio)   ALK (Xenopus laevis)   ALK (Canis familiaris)   (Compare orthologs)
Gene Ontology Term phosphorylation, protein binding, cell proliferation, membrane, protein tyrosine kinase activity, transmembrane receptor protein tyrosine kinase signaling pathway, activation of MAPK activity, ATP binding, integral to plasma membrane, receptor activity, neuron development, nucleotide binding, protein serine/threonine kinase activity, transmembrane receptor protein tyrosine kinase activity, positive regulation of NF-kappaB transcription factor activity, signal transduction, protein kinase activity, regulation of apoptosis, NF-kappaB-inducing kinase activity, protein autophosphorylation, protein phosphorylation
InterPro Term Prot_kinase_cat_dom, MAM_dom, LDrepeatLR_classA_rpt, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q580I3, Q9UM73, B2MXD7, E7EPW7
Gene-Disease Assocation NEUROBLASTOMA, SUSCEPTIBILITY TO, NEUROBLASTOMA, SUSCEPTIBILITY TO, 3; NBLST3
Search EB-eye ENSG00000171094
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-1309, E-GEOD-18005, E-GEOD-29119, E-GEOD-2450, ... (21 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-5823, E-GEOD-20081
SR
2
E-MTAB-37, E-MTAB-62
SW480
2
E-GEOD-18005, E-MTAB-37
MDA-MB-231
1
2
E-TABM-420, E-MTAB-62, E-GEOD-5823
NCIH1838
1
E-MTAB-37
MESSA
1
E-MTAB-37
121 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-13909, ... (34 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
epithelial cell
1
2
E-MEXP-2034, E-GEOD-4483, E-GEOD-10797
hematopoietic progenitor cells
1
E-MEXP-70
naive
1
E-GEOD-2649
naive CD4 T cell
1
E-MEXP-750
CD71+ early erythroid
2
1
E-AFMX-5
48 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-2069, E-GEOD-22148, E-MEXP-121, ... (41 experiments)

Factor Value U/D Experiments
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
alveolar rhabdomyosarcoma
2
E-MTAB-62, E-MEXP-121
neuroblastoma
2
E-MTAB-62, E-MTAB-37
rhabdomyosarcoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
1
2
E-GEOD-7307, E-MEXP-2034, E-MTAB-62
osteomyelitis
1
E-MTAB-62
137 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5824, E-GEOD-5099, E-MEXP-941, ... (13 experiments)

Factor Value U/D Experiments
none
2
3
E-GEOD-412, E-GEOD-5824, E-GEOD-4600, E-GEOD-1615, E-GEOD-7400 ... (5 experiments)
granulocyte-colony stimulating factor
1
E-GEOD-7400
valproic acid
1
E-GEOD-1615
no estradiol
1
E-GEOD-20081
glutamine
1
E-MEXP-941
phorbol 12-myristate 13-acetate
1
E-GEOD-4600
12 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2191, E-GEOD-1563, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-6236, E-MTAB-62

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22541, E-GEOD-22148, E-TABM-147, E-GEOD-1751, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-563

Genotype
studied in E-GEOD-1923, E-GEOD-17476, E-GEOD-18005

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-6432, E-TABM-127, E-GEOD-20504, E-MEXP-1446 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-15, ... (27 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-4600

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-MEXP-1422, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-147

Processing time: 0.503 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM